So in the present TERTIO clinical trial, we propose to determine the clinical interest and immunological efficacy of a treatment combining the CD4 helper T-inducer cancer anti-telomerase vaccine (UCPVax) with anti-PD-L1 therapy (atezolizumab) and bevacizumab in unresectable HCC by evaluation of the objective response rate at 6 months (randomized non-comparative phase II, 105 patients) according to RECIST v1.1 criteria. Here, CD274 is linked to hepatocellular carcinoma.